Innate Pharma SA
Laura Chiossone is a seasoned scientist specializing in immunology, currently serving as Science Lead for Next Generation Innovation projects and Team Leader in the Pharmacology Department at Innate Pharma since March 2018. Prior experience includes a role as Scientist PhD at CIML, where novel immune inhibitory checkpoints were identified for cancer targeting, and extensive research on immunomodulating activity of MSC and NK cells at the G. Gaslini Institute. Laura's career began with foundational studies as a PhD student focused on NK cell depletion and immunological reconstitution post-bone marrow transplant, complemented by advanced education, including multiple PhDs in Clinical and Experimental Immunology and Clinical Pathology from Università degli Studi di Genova.
This person is not in any teams
This person is not in any offices
Innate Pharma SA
2 followers
Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The Company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.